Observational study, no new intervention offered clinical trials

Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy

This study looks at why a heart medicine called mavacamten works differently for people with hypertrophic cardiomyopathy (HCM). We're trying to find out if your genes – both the one causing HCM and the one processing medicines – affect how well the treatment helps you.